ClearPoint Neuro, Inc. (NASDAQ:CLPT) on Friday said it received EU MDR Certification for its ClearPoint Navigation Software Version 3.0.2.
The ClearPoint Navigation Software Version 3.0.2 has been designed to unify the global navigation platform.
Version 3.0.2 introduces an intraoperative CT workflow. Earlier generations of ClearPoint software supported MRI-guided workflows exclusively. The 3.0.2 release extends ClearPoint navigation capabilities to the operating room.
By offering compatibility with both intraoperative CT and Cone-beam CT imaging, the software is designed to increase access to precision-guided neurosurgery for facilities without intraoperative MRI capabilities.
The ClearPoint Navigation Software Version 3.0.2, when used in conjunction with the SmartFrame XG stereotactic frame, is intended to provide precise stereotactic guidance when placing instruments or devices during neurosurgical procedures.
These procedures include biopsies, catheter and electrode insertion, including deep brain stimulation (asleep or awake) lead placement.
Earlier in January, ClearPoint Neuro released preliminary fourth-quarter of 2025 revenues of approximately $10.4 million, reflecting a 20% year-over-year growth.
The company also reported that its full-year revenue for 2025 was around $37 million, with expectations for 2026 revenues to range between $54 million and $60 million, driven by organic growth and the integration of the IRRAflow product line.
The CEO, Joe Burnett, highlighted strong momentum in the company’s core markets, including functional neurosurgery disposables and biologics, which grew by 23% and 26%, respectively.
This growth is expected to continue into 2026 as the company prepares for the commercial launch of neurocell and gene therapies.
CLPT Shows Mixed Technical Signals
Currently, the stock is trading 2.9% above its 20-day simple moving average (SMA) and 4.1% above its 50-day SMA, indicating some short-term strength. However, it remains 11.4% below its 100-day SMA and 3.6% above its 200-day SMA, suggesting mixed signals in the longer term.
The RSI is at 47.42, which is considered neutral territory, indicating that the stock is neither overbought nor oversold. Meanwhile, MACD is below its signal line, indicating bearish pressure on the stock.
The combination of neutral RSI and bearish MACD suggests mixed momentum for ClearPoint Neuro.
- Key Resistance: $16.50
- Key Support: $13.00
Over the past 12 months, shares have decreased by 20.08%, reflecting a longer-term downtrend. Currently, the stock is positioned closer to its 52-week lows than highs, indicating ongoing challenges in regaining upward momentum.
Upcoming Earnings: Analysts Eye CLPT’s Performance
Investors are looking ahead to the company’s next earnings report on February 25. Analysts expect a loss of $0.21 per share, down from a loss of $0.20 in the same quarter last year. Expected revenue of $10.4 million is up from $7.77 million from the same quarter last year.
The stock has a Buy rating among analysts with an average price target of $27.67.
ClearPoint Neuro’s Benzinga Edge Scorecard
Below is the Benzinga Edge scorecard for ClearPoint Neuro, highlighting its strengths and weaknesses compared to the broader market:
- Momentum: Bearish (Score: 37.58) — The stock is underperforming relative to the broader market.
The Verdict: ClearPoint Neuro’s Benzinga Edge signal reveals a stock that is currently facing bearish momentum. While the recent news may provide a temporary boost, the overall performance metrics suggest caution for investors.
Price Action: CLPT stock is up 13.65% at $16.15 at the last check on Friday, according to Benzinga Pro data.
Image: Shutterstock
Recent Comments